Another phase II trial in (NCT03356223) patients with locally advanced/metastatic head and neck cancer is currently evaluating abemaciclib monotherapy after failure of platinum and cetuximab or anti-EGFR-based therapy, but only in tumors harboring a homozygous deletion of CDKN2A, and/or amplification of CCND1 and/or of CDK6. Here, CDK6 is linked to head and neck cancer.